On Thursday, Barclays (LON:BARC) initiated coverage on shares of Kenvue Inc (NYSE:NYSE:KVUE), assigning an Equal Weight rating and establishing a price target of $23.00. The newly standalone company, known for its consumer health and beauty products, including brands like Tylenol, was recognized for its success in leveraging the under-penetrated nature of its consumer health categories.
Kenvue's performance in the beauty sector, however, presents a different scenario. The company's strategy for success in this area, which requires continuous innovation, effective marketing communication, and clear brand identities, is not yet apparent. Barclays notes that while Kenvue has made significant reinvestments into its business, especially within the beauty category, the anticipated turnaround may take longer than expected.
The analyst from Barclays acknowledged the structural attractiveness of Kenvue's two main categories but also expressed caution. There is perceived moderate risk to the estimates made by Wall Street as the market looks ahead to 2025. The company's efforts in reinvestment are appreciated, but the timeframe for a successful turnaround in the beauty segment remains uncertain.
The Equal Weight rating suggests that Barclays views Kenvue's stock as fairly valued at the current level, and the price target of $23.00 reflects the firm's expectations for the stock's performance in the near term. This initiation of coverage provides investors with a perspective on Kenvue's market position and its potential for growth, particularly in the consumer health and beauty sectors.
Barclays' position is a starting point for investors considering Kenvue's stock, as the company navigates its strategies in the consumer health and beauty markets. The price target and rating will likely be revisited as Kenvue progresses with its business plans and as market conditions evolve.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.